Glaxo Gives Up One Of Three Patents For Avandia In China

Law360, New York (August 18, 2004, 12:00 AM EDT) -- U.K. drug maker GlaxoSmithKline has abandoned its claim to a Chinese patent for a component of its popular diabetes drug Avandia, but is holding on to two other patents on the drug in an escalating battle with Chinese generic makers.

Glaxo dropped a countersuit against Chinese drugmakers, which challenged its patent for rosiglitazone, one of three patented ingredients in Avandia, a spokeswoman for the company told local media and newswires.

She did not give a reason for the decision, but the lawyer for the Chinese companies...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.